Molecular mechanisms of dietary restriction promoting health and longevity
CL Green, DW Lamming, L Fontana - Nature Reviews Molecular Cell …, 2022 - nature.com
Dietary restriction with adequate nutrition is the gold standard for delaying ageing and
extending healthspan and lifespan in diverse species, including rodents and non-human …
extending healthspan and lifespan in diverse species, including rodents and non-human …
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Abstract Fibroblast growth factor 21 (FGF21) is a stress-inducible hormone that has
important roles in regulating energy balance and glucose and lipid homeostasis through a …
important roles in regulating energy balance and glucose and lipid homeostasis through a …
Metabolic messengers: FGF21
KH Flippo, MJ Potthoff - Nature metabolism, 2021 - nature.com
As a non-canonical fibroblast growth factor, fibroblast growth factor 21 (FGF21) functions as
an endocrine hormone that signals to distinct targets throughout the body. Interest in …
an endocrine hormone that signals to distinct targets throughout the body. Interest in …
[HTML][HTML] FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases
EJ Tillman, T Rolph - Frontiers in endocrinology, 2020 - frontiersin.org
The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …
a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat …
Targeting adipose tissue in the treatment of obesity-associated diabetes
CM Kusminski, PE Bickel, PE Scherer - Nature reviews Drug discovery, 2016 - nature.com
Adipose tissue regulates numerous physiological processes, and its dysfunction in obese
humans is associated with disrupted metabolic homeostasis, insulin resistance and type 2 …
humans is associated with disrupted metabolic homeostasis, insulin resistance and type 2 …
Understanding the physiology of FGF21
FM Fisher, E Maratos-Flier - Annual review of physiology, 2016 - annualreviews.org
Fibroblast growth factor 21 (FGF21) is a peptide hormone that is synthesized by several
organs and regulates energy homeostasis. Excitement surrounding this relatively recently …
organs and regulates energy homeostasis. Excitement surrounding this relatively recently …
[HTML][HTML] Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
JB Funcke, PE Scherer - Journal of lipid research, 2019 - ASBMB
The breakthrough discoveries of leptin and adiponectin more than two decades ago led to a
widespread recognition of adipose tissue as an endocrine organ. Many more adipose tissue …
widespread recognition of adipose tissue as an endocrine organ. Many more adipose tissue …
Restoration of metabolic health by decreased consumption of branched‐chain amino acids
NE Cummings, EM Williams, I Kasza… - The Journal of …, 2018 - Wiley Online Library
Key points We recently found that feeding healthy mice a diet with reduced levels of
branched-chain amino acids (BCAAs), which are associated with insulin resistance in both …
branched-chain amino acids (BCAAs), which are associated with insulin resistance in both …
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
G Musso, M Cassader, R Gambino - Nature reviews Drug discovery, 2016 - nature.com
Non-alcoholic fatty liver disease—the most common chronic liver disease—encompasses a
histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) …
histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) …
FGF21 gene therapy as treatment for obesity and insulin resistance
V Jimenez, C Jambrina, E Casana… - EMBO molecular …, 2018 - embopress.org
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently
available therapies are not suited for all patients in the heterogeneous obese/T2D …
available therapies are not suited for all patients in the heterogeneous obese/T2D …